首 页   本刊简介  编委会  审稿专家  在线期刊  写作规范  广告合作  联系我们
您现在的位置:首页 => 在线期刊 => 6期丙型肝炎 => 专家论坛 =>直接抗病毒药物未增加慢性HCV感染者肝细..
直接抗病毒药物未增加慢性HCV感染者肝细胞癌的发生率
Whether antiviral therapy can reduce the incidence of hepatocellular carcinoma in patients with chronic HCV infection
文章发布日期:2017年05月04日  来源:  作者:曾庆磊,余祖江  点击次数:346次  下载次数:57次

调整字体大小:

(此处下载失败可以在在线预览处保存副本或者右键另存为)

【摘要】:2010年研究发现慢性HCV感染者经治疗获得持续病毒学应答意味着治愈,全球范围内IFN联合利巴韦林的总体治愈率为60%左右,中国的真实世界研究结果为71.1%。2013年以后,美国率先上市针对HCV的直接抗病毒药物(DAA),治愈率提高至接近100%。然而,近期有研究发现应用DAA后肝细胞癌的发生率有所升高,DAA是不是元凶目前仍有争议。笔者认为这主要是DAA的适应证覆盖了更多且疾病程度更重的终末期丙型肝炎患者所致,而这部分患者本身就是肝细胞癌的高危人群;亦不能完全排除DAA可导致机体抑癌免疫状态发生改变,未来需要从分子水平进行确证。
【Abstract】:In 2010, studies found that achievement of sustained virologic response after treatment in patients with chronic HCV infection meant cure; the overall cure rate of interferon combined with ribavirin around the world was about 60%, and the result of real-world study in China was 71.1%. In 2013, the US took the lead in launching the direct-acting antiviral agents (DAAs) for HCV, and the cure rate was increased to almost 100%. However, recent studies have found that the incidence of hepatocellular carcinoma (HCC) tends to increase after the application of DAAs, and there are still controversies over whether DAAs are the major cause of this phenomenon. In our opinion, this phenomenon is caused by the fact that the indications for DAAs cover more end-stage hepatitis C patients who are intrinsically the high-risk population of HCC; however, it cannot be excluded that DAAs may lead to the change in the body′s antitumor immune status. Studies are needed in the future to examine this issue at the molecular level.
【关键字】:肝炎, 丙型, 慢性; 癌, 肝细胞; 抗病毒药
【Key words】:hepatitis C, chronic; carcinoma, hepatocellular; antiviral agents
【引证本文】:曾庆磊, 余祖江. 直接抗病毒药物未增加慢性HCV感染者肝细胞癌的发生率[J]. 临床肝胆病杂志, 2017, 33(6): 1075-1078.

地址:长春市东民主大街519号《临床肝胆病杂志》编辑部 邮编:130061 电话:0431-88782542/3542
临床肝胆病杂志 版权所有 Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号

吉公网安备 22010402000041号